Szpital Kliniczny Im. Karola Jonschera Uniwersytetu Medycznego Im. Karola Marcinkowskiego W Poznaniu
- Address
- Ul. Szpitalna 27/33, 60-572 Poznan, Poland
Pediatric Hematology and Leukemia Research
At Szpital Kliniczny Im. Karola Jonschera Uniwersytetu Medycznego Im. Karola Marcinkowskiego w Poznaniu, clinical trials in hematology and oncology focus strongly on childhood leukemias and related blood cancers. The studies are designed to improve treatment effectiveness, reduce relapse risk, and lower serious treatment-related complications in young patients.
- Acute lymphoblastic leukemia and lymphoblastic lymphoma research aimed at improving survival and reducing relapse
- Acute myeloid leukemia studies in children, including difficult-to-treat genetic subtypes
- Myeloid leukemia in children with Down syndrome and other high-risk pediatric blood cancers
- Testing new treatment combinations and immunotherapy approaches to improve disease control
This research reflects a broad effort to refine pediatric cancer care while supporting safer, more effective therapy for children and adolescents.
Pediatric Transplantation and Cellular Therapy
The site’s transplantology program includes trials centered on hematopoietic stem cell transplantation for children with leukemia. These studies aim to optimize transplant outcomes, preserve anti-leukemia benefit, and reduce complications such as graft-versus-host disease.
- HSCT strategies for pediatric ALL and related high-risk disease
- Approaches to reduce transplant-related toxicity while maintaining treatment benefit
- Studies of supportive therapies after transplantation to help prevent relapse
- Evaluation of transplant safety and long-term outcomes in young patients
The transplantation research at this pediatric center in Poznan is closely linked to international efforts to improve outcomes for children needing advanced blood cancer treatment.
Pediatric Solid Tumor and Liver Cancer Studies
Clinical research in neoplasms also covers pediatric solid tumors, especially liver cancers. These trials explore better treatment planning, outcome improvement, and biological sample collection to support future personalized care.
- Hepatoblastoma and hepatocellular carcinoma studies in children
- Comparing treatment approaches for different risk groups
- Evaluating whether less intensive care can maintain good outcomes in selected patients
- Collecting data to improve understanding of tumor biology and treatment toxicity
These trials help advance pediatric cancer care by balancing cure rates with long-term safety.
Kidney and Gastrointestinal Inflammatory Diseases
The research portfolio includes digestive system diseases and hemic and lymphatic diseases, with additional work in nutritional and metabolic diseases. Trials in this area focus on inflammatory conditions affecting the kidneys and gastrointestinal tract, aiming to improve symptom control and reduce harmful inflammation.
- IgA nephropathy and proteinuria management in children
- Crohn's disease affecting the esophagus, stomach, and duodenum
- Testing therapies intended to lessen inflammation and protect organ function
- Evaluating whether treatment can improve disease control compared with standard care
These studies support better management of chronic pediatric inflammatory disease through more targeted treatment options.
Pediatric Respiratory and Pulmonary Vascular Research
The site also conducts trials in respiratory tract diseases, especially pulmonary arterial hypertension in children. Research in this area aims to assess safety, effectiveness, and longer-term treatment benefit for a serious condition that affects blood flow in the lungs.
- Pediatric pulmonary arterial hypertension and related vascular disease
- Evaluating medication performance in children with chronic lung circulation problems
- Studying whether treatment can improve function and disease stability
- Long-term follow-up of therapy use in pediatric patients
This work broadens the clinical research profile of the pediatric department beyond oncology and transplant care.
Supportive Care, Hemophilia, and Diabetes Studies
Research at this hospital also includes pathological conditions, signs and symptoms and selected chronic diseases that affect quality of life in children. These trials aim to improve prevention, symptom management, and early disease control in everyday pediatric care.
- Chemotherapy-induced nausea and vomiting prevention in children receiving cancer treatment
- Hemophilia studies focused on bleeding prevention and treatment effectiveness
- Type 1 diabetes trials exploring ways to slow loss of insulin-producing cells
- Evaluating supportive therapies that can make treatment safer and more tolerable
These studies show a strong interest in both disease-specific therapy and supportive care that helps children cope better with complex illnesses.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 9 therapeutic areas and 15 of 76 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 75 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 13 by active trials.
- 1GPOH gGmbH2active
lock +12 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Actelion Pharmaceuticals Ltd.3trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Szpital Kliniczny Im. Karola Jonschera Uniwersytetu Medycznego Im. Karola Marcinkowskiego W Poznaniu
lock Showing 1 of 22 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b, Randomised, Double-Blind, Placebo-Controlled, Parallel-Arm Dose Finding Study Evaluating the Efficacy and Safety of SAB-142 for Delaying the Progression of Type 1 Diabetes (T1D) in Patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D) | Sab Biotherapeutics Inc. | Phase II | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 76 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cytarabine | 8 | Unknown | 2017-10-02 | 2026-06-22 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
